Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis

Thrombosis Research

Volumn 136, Issue 4, 2015, Pages 732-738

  Sindet Pedersen, Caroline ^a,b   Pallisgaard, Jannik Langtved ^a,b   Olesen, Jonas Bjerring ^b   Gislason, Gunnar Hilmar ^a,b,c,d   Arevalo, Lourdes Cantarero ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d The Danish Heart Foundation   (Denmark)

Author keywords

Bleeding; New oral anticoagulants; Recurrent venous thromboembolism; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; MIDDLE AGED; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84941875041     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.07.022     Document Type: Article

References (32)

1. K.A. Bauer Pros and cons of new oral anticoagulants Hematol. Am. Soc. Hematol. Educ. Program 2013 2013 464 470
2. K. Saraf, P. Morris, P. Garg, P. Sheridan, and R. Storey Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations Postgrad. Med. J. 90 1067 2014 520 528
3. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, P. Mismetti, and et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 7 2014 764 772
4. P.S. Wells, M.A. Forgie, and M.A. Rodger Treatment of venous thromboembolism JAMA 311 7 2014 717 728
5. B.M. Rollins, M.A. Silva, J.L. Donovan, and A.O. Kanaan Evaluation of Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism Using a Mixed-Treatment Comparison, Meta-Analytic Approach Clin. Ther. 10 2014 1454 1464
6. S.K. Kakkos, G.I. Kirkilesis, and I.A. Tsolakis Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials Eur. J. Vasc. Endovasc. Surg. 5 2014 565 575
7. G. Agnelli, and C. Becattini Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism Hematol. Am. Soc. Hematol. Educ. Program 2013 2013 471 477
8. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, and et al. Apixaban for extended treatment of venous thromboembolism N. Engl. J. Med. 368 8 2013 699 708
9. L.A. Castellucci, C. Cameron, G. Le Gal, M.A. Rodger, D. Coyle, P.S. Wells, and et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis BMJ 347 2013 f5133
10. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, and et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
11. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J. Clin. Epidemiol. 62 10 2009 e1 e34
12. R. Core Team R: A language and environment for statistical computing 2015 R Foundation for Statistical Computing V Austria
13. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, A.S. Gallus, and et al. Oral rivaroxaban for symptomatic venous thromboembolism N. Engl. J. Med. 363 26 2010 2499 2510
14. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, D. Baanstra, and et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N. Engl. J. Med. 368 8 2013 709 718
15. G. Agnelli, P. Prandoni, M.G. Santamaria, P. Bagatella, A. Iorio, M. Bazzan, and et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators N. Engl. J. Med. 345 3 2001 165 169
16. C. Kearon, M. Gent, J. Hirsh, J. Weitz, M.J. Kovacs, D.R. Anderson, and et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N. Engl. J. Med. 340 12 1999 901 907
17. F.A. Spencer, J.M. Gore, D. Lessard, C. Emery, L. Pacifico, G. Reed, and et al. Venous thromboembolism in the elderly. A community-based perspective Thromb. Haemost. 100 5 2008 780 788
18. P. Sardar, S. Chatterjee, and D. Mukherjee Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials Drugs 73 11 2013 1171 1182
19. G. Alotaibi, K. Alsaleh, C. Wu, and M.S. McMurtry Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis Int. Angiol. 33 4 2014 301 308
20. S. Schulman, S. Granqvist, M. Holmström, A. Carlsson, P. Lindmarker, P. Nicol, and et al. The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism N. Engl. J. Med. 336 6 1997 393 398
21. A.D. Siderowf Evidence from clinical trials: can we do better? NeuroRx 1 3 2004 363 371
22. A.T. Cohen, S. Imfeld, and T. Rider Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results Adv. Ther. 31 5 2014 473 493
23. J.W. Cheng, and G. Barillari Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions J. Clin. Pharm. Ther. 39 2 2014 118 135
24. F. Scaglione New oral anticoagulants: comparative pharmacology with vitamin K antagonists Clin. Pharmacokinet. 52 2 2013 69 82
25. P. Prandoni The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations Blood Transfus. 13 2 2015 178 180
26. P. Sardar, S. Chatterjee, E. Herzog, R. Nairooz, D. Mukherjee, and J.L. Halperin Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials Can. J. Cardiol. 30 8 2014 888 897
27. S. Schulman, and M. Ogren New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism Thromb. Haemost. 96 3 2006 258 266
28. H.R. Buller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, E. Minar, and et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N. Engl. J. Med. 366 14 2012 1287 1297
29. L.A. Castellucci, C. Cameron, G. Le Gal, M.A. Rodger, D. Coyle, P.S. Wells, and et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis JAMA 312 11 2014 1122 1135
30. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, and et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N. Engl. J. Med. 361 24 2009 2342 2352
31. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, and et al. Oral apixaban for the treatment of acute venous thromboembolism N. Engl. J. Med. 369 9 2013 799 808
32. M. Crowther, W. Lim, and M.A. Crowther Systematic review and meta-analysis methodology Blood 116 17 2010 3140 3146